# A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

> **NCT05293496** · PHASE1 · COMPLETED · sponsor: **MacroGenics** · enrollment: 31 (actual)

## Conditions studied

- Advanced Solid Tumor
- Castration-Resistant Prostatic Cancer
- Malignant Melanoma
- Pancreatic Ductal Carcinoma
- Hepatocellular Cancer
- Epithelial Ovarian Cancer
- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** vobramitamab duocarmazine
- **BIOLOGICAL:** lorigerlimab

## Key facts

- **NCT ID:** NCT05293496
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-19
- **Primary completion:** 2025-06-24
- **Final completion:** 2025-08-26
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293496, "A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05293496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*